The Manufacturers Life Insurance Company Invests $75,000 in Atossa Therapeutics, Inc. (NASDAQ:ATOS)

The Manufacturers Life Insurance Company bought a new position in shares of Atossa Therapeutics, Inc. (NASDAQ:ATOS) in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 49,113 shares of the company’s stock, valued at approximately $75,000.

Other large investors have also recently bought and sold shares of the company. Renaissance Technologies LLC raised its stake in shares of Atossa Therapeutics by 11.9% during the 2nd quarter. Renaissance Technologies LLC now owns 1,550,910 shares of the company’s stock valued at $1,846,000 after buying an additional 164,540 shares during the last quarter. Bank of New York Mellon Corp grew its holdings in Atossa Therapeutics by 3,160.5% during the second quarter. Bank of New York Mellon Corp now owns 411,667 shares of the company’s stock worth $490,000 after acquiring an additional 399,041 shares during the period. Rhumbline Advisers purchased a new position in Atossa Therapeutics during the second quarter valued at approximately $161,000. SG Americas Securities LLC lifted its holdings in Atossa Therapeutics by 254.3% in the third quarter. SG Americas Securities LLC now owns 41,849 shares of the company’s stock valued at $64,000 after acquiring an additional 30,037 shares during the period. Finally, XTX Topco Ltd purchased a new stake in Atossa Therapeutics in the 2nd quarter worth approximately $29,000. Hedge funds and other institutional investors own 12.74% of the company’s stock.

Analysts Set New Price Targets

Several research firms recently issued reports on ATOS. StockNews.com cut shares of Atossa Therapeutics from a “hold” rating to a “sell” rating in a research note on Monday, November 18th. Ascendiant Capital Markets lifted their price target on Atossa Therapeutics from $6.50 to $7.00 and gave the company a “buy” rating in a research note on Monday, December 9th. Finally, HC Wainwright reiterated a “buy” rating and set a $7.00 price target on shares of Atossa Therapeutics in a research report on Thursday, December 12th.

Atossa Therapeutics Stock Down 2.8 %

ATOS opened at $1.04 on Wednesday. Atossa Therapeutics, Inc. has a twelve month low of $0.70 and a twelve month high of $2.31. The company has a market cap of $130.83 million, a PE ratio of -4.73 and a beta of 1.21. The company has a 50-day moving average price of $1.34 and a 200 day moving average price of $1.32.

Atossa Therapeutics Profile

Atossa Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer.